Publikationen
Giunta C, Baumann M, Fauth C, Lindert U, Abdalla EM, Brady AF, Collins J, Dastgir J, Donkervoort S, Ghali N, Johnson DS, Kariminejad A, Koch J, Kraenzlin M, Lahiri N, Lozic B, Manzur AY, Morton JEV, Pilch J, Pollitt RC, Schreiber G, Shannon NL, Sobey G, Vandersteen A, van Dijk FS, Witsch-Baumgartner M, Zschocke J, Pope FM, Bönnemann CG, Rohrbach M.
A cohort of 17 patients with kyphoscoliotic Ehlers-Danlos syndrome caused by biallelic mutations in FKBP14: expansion of the clinical and mutational spectrum and description of the natural history.
Genet Med. 2017 Jun 15. [Epub ahead of print]
Gotthardt F., Huber C., Thierfelder C., Grize L., Kraenzlin M., Scheidegger C., Meier C.
Determinants of bone mineral density in men with opioid dependence
J Bone Miner Metab 2017, 35: 99-107
J. A. Kanis, C. Cooper, R. Rizzoli5, B. Abrahamsen, N. M. Al-Daghri, M. L. Brandi, J. Cannata-Andia, B. Cortet, H. P. Dimai, S. Ferrar, P. Hadji, N. C. Harvey, M. Kraenzlin, A. Kurth, E. McCloskey, S. Minisola, T. Thomas, J.-Y. Reginster
Identification and management of patients at increased risk of osteoporotic fracture: Outcomes of an ESCEO expert consensus meeting
Osteoporos Int. 2017 in print
Kraenzlin M.E., Jakob F.
Schmerzen bei Erkrankungen des Knochens.
In: E. Battegay Ed. Siegenthaler's Differentialdiagnose innerer Kranheiten. 21. Auflage 2017;in print
Kraenzlin M., Meier C.
Kalziumstoffwechsel.
In: Lehrbuch Osteologie. Hrsg. Lange U. and Kurth A., in print 2017
Meier C., Uebelhart B., Aubry-Rozier B., Birkhäuser M., Bischoff-Ferrari H., Frey D., Kressig R.W., Lamy O., Lippuner K., Stute P., Suhm N., Ferrari S.
Osteoporosis drug treatment: duration and management after discontinuation. A position statement from the Swiss Association against Osteoporosis (SVGO/ASCO)
Swiss Med Wkly (2017), 147: w14484
Meier C., Jockers F., Kraenzlin M.
Systemische Mastocytose: Ein 56-jähriger Mann mit einer fortgeschrittenen Osteoporose
In: 50 Fälle Osteologie. Ed: A. Roth 2017, in print
Meier C., Kraenzlin M.
Parathormonstoffwechsel.
In: Lehrbuch Osteologie. Hrsg. Lange U. and Kurth A., in print 2017
Seelig E, Meyer S, Timper K, Nigro N, Bally M, Pernicova I, Schuetz P, Muller
B, Korbonits M, Christ-Crain M. Metformin prevents metabolic side effects during systemic glucocorticod treatment.
Europ J Endocrinol 2017, 176: 413-419
Struja T, Kaeslin M, Boesiger F, Jutzi R, Imahorn N, Kutz A, Bernasconi L, Mundwiler E, Mueller B, Christ-Crain M, Meienberg F, Ebrahimi F, Henzen C, Fischli S, Kraenzlin M, Meier C, Schuetz P.
External validation of the GREAT score to predict relapse risk in Graves' disease Results from a multicenter, retrospective study with 741 patients.
Eur J Endocrinol. 2017 Jan 18. Epub
Struja T., Kutz A., Fischli S., Meier C., Mueller B., Recher M., Schuetz P.
Personalized, immune-modulating treatments for Graves‘ disease: Fact or fiction?
Swiss Med Wkly 2017, 147: w14476
Rueegg C.S., Kriemler S., Zuercher S., Schindera C., Renner A., Hebestreit H., Meier C., Eser P., Vd Weid N.X.
A partially supervised physical activity program for adult and adolsecent survivors of childhood cancer (SURfit): Study design of a randomized controlled trial
BMC Cancer (2017), 17: 822-837
Vavanikunnel J., Meier C., Christ E
Primärer (pHPT) und sekundärer Hyperparathyreoidismus (sHPT) - Was ist wichtig für den Hausarzt?